Skip to main content
Download PDF

MicroRNA-29a-3p prevents Schistosoma japonicum-induced liver fibrosis by targeting Roundabout homolog 1 in hepatic stellate cells

Parasites & Vectors volume 16, Article number: 184 (2023) Cite this article

Abstract

Background

Schistosomiasis is a serious but neglected parasitic disease in humans that may lead to liver fibrosis and death. Activated hepatic stellate cells (HSCs) are the principal effectors that promote the accumulation of extracellular matrix (ECM) proteins during hepatic fibrosis. Aberrant microRNA-29 expression is involved in the development of fibrotic diseases. However, less is known about the role of miR-29 in Schistosoma japonicum (S. japonicum)-induced hepatic fibrosis.

Methods

The levels of microRNA-29a-3p (miR-29a-3p) and Roundabout homolog 1 (Robo1) were examined in liver tissues during S. japonicum infection. The possible involvement of the miR-29a-3p-Robo1 signaling pathway was determined. We used MIR29A conditional knock-in mice and mice injected with an miR-29a-3p agomir to investigate the role of miR-29a-3p in schistosomiasis-induced hepatic fibrosis. The functional contributions of miR-29a-3p-Robo1 signaling in liver fibrosis and HSC activation were investigated using primary mouse HSCs and the human HSC cell line LX-2.

Results

MiR-29a-3p was downregulated in humans and mice with schistosome-induced fibrosis, and Robo1 was upregulated in liver tissues. The miR-29a-3p targeted Robo1 and negatively regulated its expression. Additionally, the expression level of miR-29a-3p in schistosomiasis patients was highly correlated with the portal vein and spleen thickness diameter, which represent the severity of fibrosis. Furthermore, we demonstrated that efficient and sustained elevation of miR-29a-3p reversed schistosome-induced hepatic fibrosis. Notably, we showed that miR-29a-3p targeted Robo1 in HSCs to prevent the activation of HSCs during infection.

Conclusions

Our results provide experimental and clinical evidence that the miR-29a-3p-Robo1 signaling pathway in HSCs plays an important role in the development of hepatic fibrosis. Therefore, our study highlights the potential of miR-29a-3p as a therapeutic intervention for schistosomiasis and other fibrotic diseases.

Graphical Abstract

Background

Schistosomiasis is one of the most prevalent, but neglected, tropical infectious diseases, and it affects more than 230 million people in 78 countries, including children and young adults [1]. The two most important species that cause liver disease in humans are Schistosoma mansoni and Schistosoma japonicum (S. japonicum) [2]. The primary pathology of S. japonicum-induced schistosomiasis is egg-induced granuloma formation and fibrosis. Female adult worms living in the host mesenteric veins lay numerous eggs, most of which become trapped in the liver tissue via the portal venous system, causing a granulomatous reaction and fibrosis [3]. Hepatic fibrosis and the resulting portal hypertension are the primary causes of mortality associated with this chronic disease [4]. Elucidating the mechanisms that result in hepatic fibrosis may lead to more effective intervention strategies for schistosomiasis and a variety of fibrotic diseases.

Hepatic stellate cells (HSCs) are the main effectors of various types of hepatic fibrosis [5], including schistosome infection-induced hepatic fibrosis [6]. Quiescent HSCs are resident perisinusoidal cells located in the subendothelial space between hepatocytes and sinusoidal endothelial cells, and these cells are characterized by the presence of cytoplasmic vitamin A droplets [7]. Upon activation, HSCs gradually transform into proliferative, contractile, and fibrogenic myofibroblasts [8]. Liver injury stimulates a variety of cytokines and growth factors that activate HSCs to produce α-smooth muscle actin (α-SMA) and secrete excess extracellular matrix (ECM), which results in liver fibrosis [9, 10]. It has been shown that schistosome infection activates HSCs distributed around the periphery of egg-induced granulomas [11]. Previous studies suggested that transforming growth factor-β1 (TGF-β1) was the effector cytokine of schistosome-induced hepatic fibrosis, and it remains the classic fibrogenic cytokine driving the activation of HSCs [12,13,14]. Blocking the activation of HSCs has become one of the major strategies for therapeutic interventions for hepatic fibrosis [15].

MicroRNAs (miRNAs) are endogenous, small noncoding RNAs that negatively regulate gene expression by base pairing with the 3′ untranslated region of their target messenger RNA (mRNA) [16, 17]. Increasing evidence has demonstrated that miRNAs play important roles in maintaining cellular homeostasis under normal and diseased conditions [18]. The dysregulation of miRNA expression is involved in fibrosis in multiple organ systems, including the vasculature (pulmonary fibrosis), liver, and kidney [19,20,21,22]. Several studies showed that miRNAs play a crucial role in the pathogenesis of liver fibrosis and may be useful therapeutic targets [23, 24]. Our previous findings indicated that increased expression of miR-182 promoted HSC activation by targeting FOXO1, which resulted in the induction of hepatic fibrosis [25]. The miR-29 family consists of miR-29a, miR-29b, and miR-29c, which were significantly decreased in fibrotic livers, as demonstrated in human liver fibrosis and two different models of liver injury induced by bile duct ligation (BDL) and carbon tetrachloride (CCl4) [22, 26, 27]. However, there is no experimental evidence to demonstrate that miR-29a is involved in the occurrence or progression of schistosome infection-induced hepatic fibrosis.

Roundabout homolog 1 (Robo1) is a member of the neural cell adhesion molecular family of receptors, and it is expressed in various cell types [28, 29]. Robo1 is a critical regulator in multiple biological processes, including cell proliferation, differentiation, and migration [30, 31]. Robo1 is related to several types of cancer [32, 33] and chronic diseases, including kidney disease [34] and liver fibrosis [35]. Our previous results indicated that microRNA-29a-3p (miR-29a-3p) downregulated the expression of Robo1 to inhibit hepatocellular carcinoma cell proliferation, migration, invasion, tumor progression, and metastasis [36]. In light of these findings, we hypothesized that miR-29a-3p and Robo1 were critically involved in schistosomiasis-induced hepatic fibrosis. The present study used S. japonicum in humans and mice to investigate the role of miR-29a-3p and Robo1. We used MIR29A conditional knock-in mice and mice injected with an miR-29a-3p agomir to investigate our hypothesis and elucidate the molecular pathogenesis pathways of miR-29a-3p and Robo1 in the fibrotic changes of human and mouse livers upon exposure to schistosome infection.

Methods

Patients

Liver biopsy specimens were collected from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, between September 2015 and August 2019. Wedge biopsy specimens from normal portions of the liver were obtained from seven patients without metastatic liver carcinoma (3 colonic carcinomas and 4 gastric carcinomas) as controls. Fibrotic liver specimens were collected from nine patients with chronic schistosomiasis. The disease state of the tissues was confirmed by histopathological diagnosis. Study exclusion criteria were patients with other types of hepatitis and liver disease associated with drug or alcohol use. Unless otherwise stated, the n-values refer to the number of patients from whom tissue was obtained. Due to the limited number of tissue samples, not all samples were included in every study protocol. The demographic characteristics of the enrolled patients are summarized in Table 1.

Table 1 Patients’ demographic characteristics
Full size table

Mice

Generation of the human MIR29A conditional knock-in mouse line by CRISPR/Cas9 was outsourced to Cyagen Biosciences (Suzhou, China). The mice were created on the C57BL/6J genetic background. The gRNA (5′-GAACACTAGTGCACTTATCCTGG-3′) to the Hipp11 (H11) locus, the donor vector containing the “CAG-loxP-Stop-loxP-human MIR29A-polyA” cassette, and Cas9 mRNA were co-injected into fertilized mouse eggs to generate targeted conditional knock-in offspring. A schematic depiction of the targeting strategy is shown in Additional file 1: Fig. S1.

Animal models of S. japonicum-induced hepatic fibrosis

Six-week-old female mice were used in this study. Wild-type (WT) C57BL/6J mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Human MIR29A conditional knock-in mice were constructed by Cyagen. All animals were housed under specific pathogen-free conditions with standard laboratory food and water available ad libitum. To induce infection, seven 6-week-old female MIR29A mice and seven age-matched female WT C57BL/6J mice were exposed percutaneously to 16 ± 1 S. japonicum cercariae (Chinese mainland strain) obtained from infected Oncomelania hupensis snails purchased from Nanjing Institute of Schistosomiasis Prevention and Control (Nanjing, China). Seven age- and sex-matched noninfected mice were used as controls.

Treatment of animals

To determine whether miR-29a-3p was sufficient to reverse egg-induced hepatic fibrosis, an miR-29a-3p agomir (RiboBio, Guangzhou, China) was used. The miR-29a-3p agomir and negative control (NC) agomir were dissolved in phosphate buffer saline (PBS) according to the manufacturer’s instructions and diluted in PBS to a final bath concentration of 10 nmol/500 μl. The infected mice were treated orally with 300 mg/kg praziquantel for 2 consecutive days to kill the parasites at 6 weeks post-infection, and the mice received the miR-29a-3p agomir or NC agomir at a dose of 10 nmol per mouse or 500 μl PBS via tail vein every 4 days for 28 days. The mice were harvested 10 weeks post-infection for further analysis.

Liver histopathology and fibrosis measurement

To estimate the egg burden, 0.2 g of each liver was digested overnight with 20 ml 4% potassium hydroxide, and the numbers of eggs were counted under a microscope. Total eggs per gram in the liver were calculated using the following formula: the number of eggs calculated × 5. The liver or spleen index was calculated with the following formula: (total weight of mouse liver or spleen/total weight of mouse body) × 100% [12, 37, 38]. The size of egg granulomas was measured in Mayer’s H&E sections using a calibrated measuring eyepiece, and the extent of fibrosis was evaluated by Masson’s trichrome staining of sections, as previously described [12]. The total fibrosis score was determined by multiplying the density and area of each granuloma (for a maximum score of 16). The hydroxyproline content in the liver was detected using a colorimetric assay kit according to the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Serum biochemistry

Approximately 1 ml of blood was sampled from mice via eyeball extirpation. The blood was incubated for 4 h at room temperature to allow clot formation and then centrifuged (3500RPM, 10 min) to separate the serum from the clot. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using a Siemens Advia 1650 automatic analyzer.

Isolation of primary HSCs, hepatocytes, and Kupffer cells

The liver was initially digested in situ with 0.05% collagenase type IV at 37 °C with bath shaking for 30 min. Hepatocytes were isolated via centrifugation of the resulting cell suspension at 50×g for 3 min and purified via centrifugation at 50×g for 2 min. After hepatocytes were pelleted, the supernatant containing nonparenchymal cells was centrifuged at 450×g for 8 min. HSCs were isolated from nonparenchymal cells using a 15% (w/v) and 11.5% (w/v) iodixanol gradient (OptiPrep; Stemcell Technologies, Vancouver, British Columbia, Canada) at 1450×g for 20 min. To further purify HSCs, we depleted HSCs of Kupffer cells (KCs) using a biotin-conjugated anti-CD271 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) and anti-biotin MicroBeads (Miltenyi Biotec). The purity was > 97%, and the viability was > 95%. Representative results for the purification of HSCs are shown in Additional file 2: Fig. S2.

Cell culture and in vitro treatment

LX-2 is a well-characterized cell line derived from human HSCs, and these cells were acquired from the Cell Collection Center of Wuhan University (China). Primary HSCs and LX-2 cells were seeded into plastic plates and cultured in DMEM (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA) and 100 μg/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cell cultures were maintained at 37 °C in a humidified incubator at 5% CO2.

LX-2 cells (2.5 × 105 cells/well) were plated in six-well plates with or without the presence of recombinant TGF-β1 (PeproTech). To determine the effects of miR-29a-3p in vitro, LX-2 cells were transfected with exogenous hsa-miR-29a-3p (miRBase: MIMAT0000086). The cells were transfected with 50 nM miR-29a-3p mimics, 100 nM miR-29a-3p inhibitors or their negative controls using a riboFECT™ CP Transfection Kit (RiboBio, Guangzhou, China) as described previously [39]. Briefly, 10 × riboFECT™ CP buffer was diluted to 1 ×. The transfection system was the mixture of 1 × riboFECT™ CP buffer, riboFECT™ CP reagent, and mimic (50 nM) or inhibitors (100 nM), and the mixture was transfected into LX-2 cells; 48 h after transfection, the cells of each experimental group were re-suspended, collected, and subjected to downstream experiments.

Immunohistochemistry and immunofluorescence

Human and mouse liver samples were fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, and cut into 4-µm-thick sections. For immunohistochemistry, horseradish peroxidase (HRP)-conjugated secondary antibodies (PeproTech Inc., USA) were used for immunostaining with the following primary antibodies: rabbit polyclonal anti-Robo1 (1:50, ab7279, Abcam, Cambridge, MA, USA), rabbit polyclonal anti-collagen I (1:100, 14695-1-AP, ProteinTech, Chicago, IL, USA), and rabbit monoclonal anti-α-SMA (1:500, ab108424, Abcam). For immunofluorescence staining, tissue sections were incubated with primary antibodies against Robo1 (1:50, ab7279, Abcam), α-SMA (1:200, BM0002, Boster Biological Technology, Wuhan, China), and desmin (1:100, ab227651, Abcam), followed by incubation with Alexa Fluor 594- and Alexa Fluor 488-conjugated secondary antibodies (1:200, Invitrogen, Carlsbad, CA, USA). All sections were stained with 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) to visualize cell nuclei. At least three liver sections were included in each group. The stained sections were viewed under a microscope (Nikon Eclipse Ci), and images were captured using a high-resolution digital camera (Nikon digital sight DS-FI2).

RNA extraction and analysis

Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. Real-time quantitative polymerase chain reaction (qPCR) was performed as previously described [40]. The expression levels of Robo1, Col1α1, Col3α1, α-SMA, and TGF-β1 were determined using the SYBR Green Master Mix Kit (Takara, Kusatsu, Japan). The expression level of miR-29a-3p was determined with a Bulge-Loop miRNA qRT-PCR Starter Kit (RiboBio, Guangzhou, China) according to the manufacturer’s protocol. Sequence-specific primers for U6 and miR-29a-3p were synthesized by RiboBio (Guangzhou, China). The endogenous controls in this study were U6 snRNA and GAPDH, and the 2−ΔΔCt method was used to calculate the fold change in the expression of all mRNAs and miR-29a-3p. The human and mouse primer sequences are presented in Table 2.

Table 2 Primer sequences used in this study
Full size table

Western blotting

Total cell protein was extracted on ice with RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) in the presence of freshly added protease inhibitors (Boster Biological Technology, Wuhan, China) and quantified by BCA assay (Pierce, Cramlington, UK). A total of 30 μg/lane protein extract was separated via 10% PAGE (Beyotime Biotechnology, Shanghai, China), followed by transfer to a PVDF membrane (Millipore Corp., Billerica, MA, USA). Nonspecific binding was blocked with 5% nonfat milk in TBST. The membrane was incubated with rabbit anti-Robo1 (1:1000, ab7279, Abcam, Cambridge, MA) overnight at 4 °C. The membranes were further incubated with HRP-conjugated anti-rabbit secondary antibodies and detected using enhanced chemiluminescence (ECL; Abbkine, Redlands, CA, USA). Rabbit anti-GAPDH (1:2000, 10494-1-AP, ProteinTech, Chicago, USA) was used as an internal standard. Densitometry was performed using ImageJ software.

Statistical analysis

The experimental results are expressed as the mean ± standard deviation (SD). Statistical significance between experimental groups was assessed using the two-tailed Student’s t test and one-way ANOVA with Tukey’s correction. The clinical results from patients are expressed as the median and interquartile range. Due to the skewed distributions of most patient variables, the Mann-Whitney U test and Kruskal-Wallis with Dunn’s multiple comparisons posttest were applied. For categorical data, the χ2 test or Fisher’s exact test was performed to determine differences between groups. Spearman’s rank test was used for correlations. All statistical analyses were performed with GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA) or SPSS 25.0 (SPSS, Chicago, IL). P values < 0.05 were considered significant.

Results

Decreased miR-29a-3p expression and increased Robo1 expression in liver tissues of patients with schistosomiasis

To examine the expression of miR-29a-3p and Robo1 in liver specimens, liver biopsy was performed in chronic schistosomiasis and control patients. The fibrotic liver tissues had larger fibrotic areas and more collagen deposition, and S. japonicum eggs were observed in the liver specimen sections of patients with schistosomiasis (Fig. 1A). The level of miR-29a-3p in the fibrotic group was significantly lower than the control group, and the level of Robo1 mRNA was increased (Fig. 1B, C). Immunoblots were analyzed, and the level of Robo1 transcription was confirmed (Fig. 1D, E). To further evaluate the functional effects of Robo1, we analyzed Robo1 in liver tissues by immunohistochemistry. The fibrotic tissues showed stronger Robo1 staining than the control liver tissues, and the Robo1-positive cells were localized primarily in areas of inflammation and fibrosis (Fig. 1F). Immunofluorescence staining was used to detect the expression of Robo1 and the presence of HSCs, which are the main effector cells in various types of hepatic fibrosis and play an important role in linking hepatic inflammation to fibrogenesis. The colocalization of Robo1 and HSCs was observed, particularly in the livers of patients with schistosomiasis (Fig. 1F). In addition, we found significant correlations between the levels of miR-29a-3p and Robo1 and portal vein diameter and spleen thickness in patients with schistosomiasis (Fig. 1G–J). These data suggested that miR-29a-3p and Robo1 may be involved in the progression of schistosome-induced hepatic fibrosis.

Fig. 1
figure 1

Decreased miR-29a-3p expression and increased Robo1 expression in liver tissues of patients with schistosomiasis. A Paraffin-embedded sections of liver tissues from patients were stained with H&E, Masson's trichrome, and Sirius Red. Scale bar, 200 μm. B, C Total RNA was extracted for qPCR analysis of miR-29a-3p and Robo1 expression levels. Control (n = 7), fibrosis (n = 9). D, E The expression of Robo1 was determined by western blotting. Image density was quantified using ImageJ and normalized to GAPDH. F Representative immunohistochemical staining of Robo1 and immunofluorescence staining of Robo1 (green) colocalization with α-SMA (red) in liver sections was detected. Yellow arrows denote positive cells. Scale bar, 50 μm. G–J Correlations between the mRNA levels of miR-29a-3p and Robo1 and portal vein diameter and spleen thickness in patients with schistosomiasis (n = 9). I The larger dot shows data from two patients. Data are presented as the median and interquartile range (B, C and E). All data are representative of at least two independent experiments. Significance was calculated using the Mann-Whitney U test (B, C and E) or Spearman’s rank test (G–J). *P < 0.05, ***P < 0.001. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1

Full size image

miR-29a-3p is downregulated in murine schistosomiasis and directly targets and negatively regulates Robo1 in HSCs

Liver samples from mice at various time points after S. japonicum infection were collected. Robo1 is a potential target of miR-29a-3p, as predicted by the TargetScan database (www.targetscan.org). To analyze the relationship between miR-29a-3p and Robo1, we evaluated their expression during the progression of hepatic schistosomiasis. We found that the expression of miR-29a-3p began to decrease in the liver at 6 weeks post-infection and reached its lowest levels at weeks 8 and 12 (Fig. 2A). In contrast, the expression level of Robo1 was significantly elevated at 8 weeks post-infection (Fig. 2B–D). In addition, miR-29a-3p downregulation was primarily observed in isolated hepatocytes and HSCs of infected mice (Fig. 2E). We also analyzed the relative expression of miR-29a-3p in different hepatic cell types by qPCR and found that miR-29a-3p was primarily present in isolated primary HSCs rather than in hepatocytes or KCs of uninfected livers. The miR-29a-3p expression level was significantly downregulated in HSCs from infected livers compare to hepatocytes and KCs (Fig. 2F). We also performed immunochemistry staining for Robo1 and observed that Robo1-producing cells were primarily located in the periphery of egg granulomas (Fig. 2G). Immunofluorescence double-staining revealed the colocalization of Robo1 and α-SMA (Fig. 2G), indicating that activated HSCs expressed Robo1 in vivo. The expression of miR-29-3p in HSCs began to decrease at 6 weeks post-infection, but the level of Robo1 mRNA was increased at this time (Fig. 2H, I). In addition, a negative correlation was observed between miR-29a-3p and Robo1 expression by Spearman’s correlation analysis (R = − 0.8301, P < 0.0001; Fig. 2J). Taken together, these results suggest that the activated HSCs in infected livers are a source of Robo1, and Robo1 is a potential target of miR-29a-3p in HSCs.

Fig. 2
figure 2

Analysis of miR-29a-3p and Robo1 expression in murine schistosomiasis. A, B The expression of miR-29a-3p and Robo1 in liver samples during infection was detected by qPCR (n = 4–5). C, D Robo1 protein was determined by western blotting, quantified using ImageJ, and normalized to GAPDH (n = 6). E, F Primary hepatocytes (Heps), Kupffer cells (KCs), and hepatic stellate cells (HSCs) were isolated from uninfected and infected (8 weeks post-infection) livers, and the level of miR-29-3p was determined by qPCR (n = 3). G Representative immunohistochemical staining of Robo1 and immunofluorescence staining of Robo1 (green) colocalization with α-SMA (red) in liver sections were detected. Yellow arrows denote positive cells. Scale bar, 50 μm. H, I Primary HSCs were isolated from liver tissues, and the expression of miR-29a-3p and Robo1 in HSCs was detected by qPCR (n = 4). J Correlations between the mRNA levels of Robo1 and miR-29a-3p in the HSCs of mice (n = 20). Data are presented as the mean ± SD from two independent experiments. Significance was determined by the two-tailed Student’s t test (A, B, D, E, H, and I) or one-way ANOVA with Tukey’s correction for comparisons between two groups (F) or Spearman’s rank test (J). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with 0W samples (A, B, D, H, and I) . miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1; Heps: hepatocytes; KCs: Kupffer cells; HSCs: hepatic stellate cells; ns: not significant

Full size image

Our previous study used a dual-luciferase reporter gene assay to demonstrate that Robo1 was a direct target of miR-29a-3p [36]. The present study showed that stimulation of LX-2 cells with TGF-β1, which is a typical profibrotic gene in the progression of hepatic fibrosis, downregulated the mRNA expression of miR-29a-3p and upregulated the level of Robo1 mRNA (Fig. 3A, B). Furthermore, we transfected miR-29a-3p mimics or inhibitors into LX-2 cells and quantified the levels of miR-29a-3p and Robo1 by qPCR and western blotting. As expected, miR-29a-3p was elevated in the miR-mimic group and reduced in the miR-inhibitor group (Fig. 3C). At both the mRNA and protein levels, the elevation of miR-29a-3p distinctly reduced the expression of Robo1, and miR-29a-3p depletion significantly increased the expression of Robo1 (Fig. 3D–F). Taken together, these data indicate that Robo1 is a direct target of miR-29a-3p in HSCs.

Fig. 3
figure 3

Validation of the relationship between miR-29a-3p and Robo1. A, B LX-2 cells were exposed to 10 ng/ml TGF-β1 for 48 h, and the expression of miR-29a-3p and Robo1 was detected by qPCR (n = 3). C–F LX-2 cells were cultured on a plastic plate and transfected with 50 nM miR-29a-3p mimics, 100 nM miR-29a-3p inhibitors, or their negative controls (NC) for 48 h. The expression of miR-29a-3p and Robo1 was determined by qPCR (n = 3) (C, D) and western blotting (n = 3–4) (E, F). Data are presented as the mean ± SD. All data are representative of at least three independent experiments. Significance was determined by the two-tailed Student’s t test (A–D, F). *P < 0.05, **P < 0.01, ***P < 0.001. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1

Full size image

MIR29A mice develop liver injury and fibrosis less readily during schistosome infection

To evaluate the effects of miR-29a-3p-Robo1 signaling on the pathogenesis of liver fibrosis, we established a model of S. japonicum-induced hepatic fibrogenesis in human MIR29A conditional knock-in mice. WT mice underwent the same treatment as controls. Compared with WT mice, MIR29A mice showed a higher level of miR-29a-3p in the heart (approximately 2.0-fold), liver (approximately 1.8-fold), spleen (approximately 3.2-fold), and kidney (approximately 2.2-fold) (Additional file 3: Fig. S3). Morphological changes in liver and spleen samples showed a moderate granulomatous response and splenomegaly in the S. japonicum-infected MIR29A mice compared with the infected WT mice (Fig. 4A). These results were confirmed by the reduced levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse serum and further confirmed by the liver and spleen indices (Fig. 4B–E). Notably, the S. japonicum-infected MIR29A mice exhibited a significant reduction in ECM deposits, as shown by hydroxyproline quantification (Fig. 4F), Masson’s trichrome staining, and Sirius Red staining (Fig. 4A, G and H), and a marked reduction in the size of hepatic granulomas as visualized by H&E staining (Fig. 4A, I). A reduction in fibrosis was further confirmed by immunohistochemical staining and qPCR-based quantification of fibrosis-associated gene expression in the livers of infected mice. Immunohistochemical staining for collagen I and α-SMA and the amounts of Col1α1, Col3α1, α-SMA, and TGF-β1 mRNA were markedly reduced in the S. japonicum-infected MIR29A mice compared with the infected WT mice (Fig. 4A, J–M). However, there was no significant change in egg burden between the two infected groups, which indicated that miR-29a treatment had no effect on parasite reproduction and survival (Additional file 4: Fig. S4A).

Fig. 4
figure 4

MIR29A mice developed liver injury and fibrosis less readily during schistosome infection. MIR29A mice and WT mice were infected percutaneously with 16 Schistosoma japonicum cercariae or remained uninfected. Liver and spleen samples were harvested at 10 weeks post-infection. A Macrograph of livers and spleens from MIR29A mice and WT mice in both the uninfected and infected groups. Scale bar, 1 cm. H&E, Masson's trichrome and Sirius Red staining of liver sections and immunohistochemical staining for collagen I and α-SMA. Scale bar, 50 μm. B, C Liver and spleen indices were determined (n = 7). D, E Serum ALT and AST levels were measured (n = 7). F Collagen content in livers determined as the hydroxyproline content (n = 7). G Fibrosis scores measured from Masson's trichrome staining of liver sections (n = 7). H Areas positive for Sirius Red staining were measured using IPP software (n = 7). I Granuloma size was measured from H&E-stained liver sections (n = 7). J–M The expression of Col1α1, Col3α1, α-SMA, and TGF-β1 in livers during infection was detected by qPCR (n = 7). Data are presented as the mean ± SD of three independent experiments. Multiple comparisons were performed by one-way ANOVA with Tukey’s correction for comparisons between two groups (B-M). **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with infected WT samples. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1; ALT: alanine aminotransferase; AST: aspartate aminotransferase

Full size image

We next evaluated the level of Robo1 in these mice. Robo1 mRNA expression was significantly lower in the liver tissues of MIR29A mice than in WT mice in the uninfected and infected groups (Fig. 5A). Robo1 protein was decreased in the liver tissues of S. japonicum-infected MIR29A mice compared with infected WT mice, as determined by western blotting. Although the uninfected MIR29A mouse group exhibited a slight reduction in Robo1 expression compared with the uninfected WT mouse group, the difference was not statistically significant (Fig. 5B, C). We next investigated whether the overexpression of miR-29a prevented schistosomiasis-induced HSC activation. We isolated primary HSCs from mice and found that HSCs in infected mouse liver tissues expressed Robo1 in vivo based on immunofluorescence staining. Furthermore, the fluorescence intensity of Robo1 was decreased in the infected MIR29A mice compared with the infected WT mice (Fig. 5D). The amounts of Col1α1, Col3α1, α-SMA, and TGF-β1 mRNA were markedly reduced in the infected HSCs of MIR29A mice compared with WT mice (Fig. 5E–H). These results suggested that miR-29a overexpression reduced the expression of Robo1 and prevented schistosomiasis-induced HSC activation.

Fig. 5
figure 5

MIR29A mice were better able to prevent HSC activation during schistosome infection. A The expression level of Robo1 in livers was determined by qPCR (n = 7). B, C Robo1 protein was determined by western blotting, quantified using ImageJ, and normalized to GAPDH (n = 6). D–H Primary HSCs were isolated from the liver tissues of mice. D Representative immunofluorescence staining of Robo1 (green) colocalization with α-SMA (red) in primary HSCs was detected. Insets show a higher magnification of the outlined area. Scale bar, 50 μm. E–H The expression of Col1α1, Col3α1, α-SMA, and TGF-β1 in primary HSCs during infection was detected by qPCR (n = 7). Data are presented as the mean ± SD from two independent experiments. Significance was determined by one-way ANOVA with Tukey’s correction for comparisons between two groups (A, C, E–H). ##P < 0.01, compared with uninfected WT samples. **P < 0.01, ****P < 0.0001, compared with infected WT samples. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1

Full size image

miR-29a-3p agomir-mediated elevation of miR-29a-3p has therapeutic potential for schistosome infection-induced hepatic fibrosis

To verify whether miR-29a-3p contributed to reversing egg-induced hepatic fibrosis, mice were infected with a moderate dose of parasites. At 6 weeks post-infection, when hepatic fibrosis was clearly manifested, all infected mice were treated with praziquantel to kill the parasite and then injected with miR-29a-3p agomir, NC agomir, or PBS every 4 days for 28 days and necropsied at 10 weeks post-infection (Fig. 6A). Liver and spleen samples from the miR-29a-3p agomir-treated group exhibited a moderate granulomatous response and splenomegaly (Fig. 6B). Antifibrosis treatment significantly reduced the liver and spleen indices (Fig. 6C, D). Furthermore, the mice treated with the miR-29a-3p agomir showed significant reductions in circulating levels of ALT and AST, suggesting that the treatment alleviated hepatocellular damage (Fig. 6E, F). Mice that received the miR-29a-3p agomir exhibited a significant reduction in ECM deposition, as shown by hydroxyproline quantification (Fig. 6G), Masson’s trichrome staining, and Sirius Red staining (Fig. 6B, H and I), and a marked reduction in the size of hepatic granulomas, as visualized on H&E staining (Fig. 6B, J). However, the livers showed no significant change in egg burden among the three infected groups (Additional file 4: Fig. S4B). Consistently, representative immunohistochemical staining and qPCR analysis demonstrated reduced expression levels of fibrosis markers in the livers of mice treated with the miR-29a-3p agomir (Fig. 6B, K–N).

Fig. 6
figure 6

miR-29a-3p agomir-mediated elevation of miR-29a-3p partially reversed schistosome-induced hepatic fibrosis. Mice were infected percutaneously with 16 Schistosoma japonicum cercariae or remained uninfected. At 6 weeks post-infection, the infected mice were treated with praziquantel to kill the parasites and then received miR-29a-3p agomir, NC agomir, or PBS every 4 days for 28 days. Mice were necropsied at 10 weeks post-infection. A Time schedule for parasite infection and administration of anti-parasite drug or miR-29a-3p agomir and sample withdrawal. B Macrographs of livers and spleens from uninfected mice, infected mice, and infected mice treated with miR-29a-3p agomir. Scale bar, 1 cm. H&E, Masson's trichrome, and Sirius Red staining of liver sections and immunohistochemical staining for collagen I and α-SMA. Scale bar, 50 μm. C, D Liver and spleen indices were determined (n = 3–5). E, F Serum ALT and AST levels were measured (n = 5). G Collagen content in livers was determined by the hydroxyproline content (n = 4–5). H Fibrosis scores measured from Masson's trichrome staining of liver sections (n = 5). I Areas positive for Sirius Red staining were measured using IPP software (n = 5). J Granuloma size measured from H&E-stained liver sections (n = 5). K–N The expression of Col1α1, Col3α1, α-SMA, and TGF-β1 in livers during infection was detected by qPCR (n = 4). Data are presented as the mean ± SD of three independent experiments. Multiple comparisons were performed by one-way ANOVA with Tukey’s correction for comparisons between two groups (C–N). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1; ALT: alanine aminotransferase; AST: aspartate aminotransferase

Full size image

As expected, significantly elevated miR-29a-3p expression was observed in the infected mice treated with miR-29a-3p agomir compared with the NC agomir and PBS groups (7.2- to 9.9-fold) (Fig. 7A), which resulted in markedly decreased Robo1 expression, as determined by qPCR and western blotting (Fig. 7B–D). Similar to that in MIR29A mice, colocalization of Robo1 and α-SMA+ HSCs was detected in the livers of infected mice. Meanwhile, the Robo1 expression in HSCs of infected mice treated with miR-29a-3p agomir was lower than in the infected mice treated with the NC agomir or PBS (Fig. 7E). The mRNA levels of Col1α1, Col3α1, α-SMA, and TGF-β1 were also downregulated in the infected HSCs of mice treated with the miR-29a-3p agomir (Fig. 7F–I). Taken together, these data demonstrated that miR-29a-3p upregulation reduced Robo1 expression and prevented schistosomiasis-induced HSC activation.

Fig. 7
figure 7

miR-29a-3p agomir-mediated elevation of miR-29a-3p prevented HSC activation during schistosome infection. A, B miR-29a-3p and Robo1 expression levels in livers were determined by qPCR (n = 3–4). C, D Robo1 protein was determined by western blotting, quantified using ImageJ, and normalized to GAPDH (n = 3). E–I Primary HSCs were isolated from the liver tissues of mice. E Representative immunofluorescence staining of Robo1 (green) colocalization with α-SMA (red) in primary HSCs. Scale bar, 100 μm. F–I The expression of Col1α1, Col3α1, α-SMA, and TGF-β1 in primary HSCs during infection was detected by qPCR (n = 3–4). Data are presented as the mean ± SD from two independent experiments. Significance was determined by one-way ANOVA with Tukey’s correction for comparisons between two groups (A, B, D, F–I). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1

Full size image

Activation of miR-29a-3p-Robo1 signaling mediates HSC activation in vitro

We next investigated whether miR-29a-3p prevented TGF-β1-induced HSC activation. Using a well-validated immortalized human HSC cell line (LX-2), we found that the overexpression of miR-29a-3p significantly attenuated the mRNA levels of Col1α1, Col3α1, α-SMA, and TGF-β1 in LX-2 cells in the presence of TGF-β1 (Fig. 8A–D). Furthermore, miR-29a-3p mimics markedly downregulated Robo1 in LX-2 cells in the presence of TGF-β1 (Fig. 8E, F). These results demonstrated that miR-29a-3p overexpression attenuated HSC activation by inhibiting Robo1 pathways both in vivo and in vitro.

Fig. 8
figure 8

Overexpression of miR-29a-3p attenuated HSC activation by inhibiting Robo1 pathways. LX-2 cells were pretreated with 50 nM miR-29a-3p mimics or their negative controls for 6 h, TGF-β1 (10 ng/ml) was added to the medium, and the expression levels of fibrosis markers and Robo1 were determined after 48 h of incubation. A–E The expression of Col1α1, Col3α1, α-SMA, TGF-β1, and Robo1 in LX-2 cells was detected by qPCR (n = 3–6). F Robo1 protein was determined by western blotting, quantified using ImageJ, and normalized to GAPDH (n = 4). Data are presented as the mean ± SD of three independent experiments. Multiple comparisons were performed by one-way ANOVA with Tukey’s correction for comparisons between two groups (A–F). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. miR-29a-3p: microRNA-29a-3p; Robo1: Roundabout homolog 1

Full size image

Discussion

It has been previously suggested that the regulation and function of miRNAs is highly organ- and cell-type specific [41]. HSCs are the main source of myofibroblasts in the liver [5]. Our findings provide evidence for a functional role of miR-29a-3p in human and murine schistosome infection-induced hepatic fibrosis. Our data showed that miR-29a-3p was downregulated in HSCs during hepatic fibrosis, and Robo1 was upregulated. Notably, our findings suggest that miR-29a-3p partially reverses schistosome-induced hepatic fibrosis by targeting Robo1 to prevent schistosomiasis-induced HSC activation during infection.

MiR-29 family members are considered fibromiRs and have been shown to be dysregulated during the process of fibrosis in multiple organs [42]. These molecules regulate multiple collagen isoforms and other ECM components [43]. In general, decreased expression of miR-29 family members is associated with increased ECM deposition and fibrosis in various tissues. The role of miR-29 species was widely studied in animal models and patient biopsies of liver fibrosis [17, 26, 27]. However, no study to date has examined the role of miR-29 in hepatic fibrosis caused by schistosomiasis. In the present study, we found that miR-29a-3p was decreased in liver tissues with schistosomiasis-induced hepatic fibrosis. Previous studies identified that Robo1, as a potential target of miR-29a-3p, was a TGF-β1 target gene in mammary cells [44], which indicated that Robo1 may be involved in the progression of hepatic fibrosis. Meanwhile, we examined the expression of Robo1 in control and schistosomiasis patients. Our results showed that the expression level of Robo1 was significantly higher in liver tissues with hepatic fibrosis. In addition, the mRNA levels of miR-29a-3p and Robo1 in the liver tissues of fibrosis patients were related to portal vein diameter and spleen thickness, which increased in parallel with the extent of hepatic fibrosis [45, 46]. More importantly, we showed that Robo1-producing cells were primarily located in HSCs. We further found that Robo1 expression in HSCs was significantly increased after infection. These results suggest that miR-29a-3p and Robo1 are involved in the pathogenesis of liver fibrosis via HSCs during schistosome infection.

To further confirm the roles of miR-29a-3p and Robo1 in vivo, we established a murine model of S. japonicum infection based on information from previous studies [6, 47]. Compared with the uninfected group, the schistosome-infected mice showed lower miR-29a-3p and higher Robo1 expression in liver tissues, and these expression levels were associated with the advanced stage of liver fibrosis. In addition, the miR-29a-3p expression level was significantly downregulated in HSCs of infected mice relative to hepatocytes and KCs. Consistently, our data also indicated that Robo1 production primarily co-localized with HSCs during schistosome infection. Furthermore, the targeting relationship between miR-29a-3p and Robo1 was confirmed using primary mouse HSCs and the human HSC cell line LX-2. These results support our functional data on the role of miR-29a-3p-Robo1 signaling in HSCs and suggest that this signaling is involved in the pathogenesis of liver fibrosis via HSCs during schistosome infection.

The abnormal activation of HSCs has long been established as a critical event during the pathogenesis of hepatic fibrosis [5]. Previous studies demonstrated the presence of activated HSCs in the periphery of S. japonicum egg granulomas in murine and human infections, and these cells are likely effector cells that contribute to granuloma-associated fibrosis, which emphasizes the importance of stellate cell modulators in the progression of hepatic schistosomiasis [6]. Increasing evidence suggests that miR-29a has antifibrotic activity. Huang et al. reported that miR-29a-overexpressing transgenic mice ameliorated liver fibrosis by modulating the profibrogenic phenotype of HSCs after BDL or a high-fat diet [48, 49]. One promising study demonstrated accelerated recovery from CCl4-induced liver fibrosis following miR-29a administration via the tail vein [50]. Our study demonstrated that the overexpression of miR-29a-3p in schistosome-infected mice significantly hindered hepatocellular damage and hepatic fibrosis. Furthermore, miR-29a-3p overexpression significantly reduced Robo1 expression in activated HSCs and lessened schistosomiasis-induced HSC activation. TGF-β1 is the most potent pro-fibrogenic cytokine [51]. Previous studies identified that TGF-β1 played an important role in schistosomiasis pathogenesis [52]. To investigate the interaction between miR-29a-3p and Robo1 and the effect of this interaction on HSC activation, we transfected an miR-29a-3p agomir into LX-2 cells, followed by exposure to TGF-β1. As expected, we found that the overexpression of miR-29a-3p significantly decreased TGF-β1-induced Robo1 and collagen expression. These data collectively demonstrated that miR-29a-3p-Robo1 signaling in HSCs mediated the pathogenesis of hepatic fibrosis, and miR-29a-3p overexpression had a beneficial effect on schistosome-induced hepatic fibrosis by reducing Robo1 expression and preventing HSC activation during infection.

As illustrated above, our results provide both experimental and clinical evidence that the miR-29a-3p-Robo1 signaling pathway in HSCs plays an important role in the development of hepatic fibrosis and strongly suggest that miR-29a-3p overexpression can reverse schistosome-induced hepatic fibrosis by suppressing HSC activation during infection. Although praziquantel can effectively target and kill schistosomes, the progression of hepatic fibrosis persists [53]. To date, there are no approved antifibrotic therapies. Our data clearly demonstrated that miR-29a-3p overexpression alleviated such a hepatic fibrosis by suppressing HSC activation. Therefore, miR-29a-3p constitutes a promising candidate for the development of therapeutic tools to prevent or treat hepatic fibrosis. However, further studies are clearly warranted.

Conclusions

Our results revealed that miR-29a-3p-Robo1 signaling in HSCs mediated the pathogenesis of hepatic fibrosis, and overexpression of miR-29a-3p had a beneficial effect on schistosome-induced hepatic fibrosis by reducing the expression of Robo1 and preventing the activation of HSCs during infection. Therefore, our study provides insights into the mechanisms of miR-29a-3p regulation of schistosomiasis hepatic fibrosis and highlights the potential of miR-29a-3p as a therapeutic intervention for fibrotic diseases.

Availability of data and materials

All data supporting the conclusions of this study are included in the article.

Abbreviations

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

α-SMA:

α-Smooth muscle actin

BDL:

Bile duct ligation

CCl4 :

Carbon tetrachloride

ECM:

Extracellular matrix

FBS:

Fetal bovine serum 

Heps:

Hepatocytes

HSCs:

Hepatic stellate cells

KCs:

Kupffer cells

miRNAs:

MicroRNAs

miR-29a-3p:

MicroRNA-29a-3p

mRNA:

Messenger RNA  PBS  Phosphate buffer saline

PBS :

Phosphate buffer saline

Robo1:

Roundabout homolog 1

S. japonicum :

Schistosoma japonicum

TGF-β1:

Transforming growth factor-β1

References

  1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383:2253–64.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85:148–54.

    Article  CAS  PubMed  Google Scholar 

  3. Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol. 2014;36:347–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kamdem SD, Moyou-Somo R, Brombacher F, Nono JK. Host regulators of liver fibrosis during human schistosomiasis. Front Immunol. 2018;9:2781.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–72.

    Article  CAS  PubMed  Google Scholar 

  6. Bartley PB, Ramm GA, Jones MK, Ruddell RG, Li Y, McManus DP. A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol. 2006;36:993–1001.

    Article  CAS  PubMed  Google Scholar 

  7. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2004;1:98–105.

    Article  PubMed  Google Scholar 

  9. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.

    Article  CAS  PubMed  Google Scholar 

  11. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106–18.

    Article  PubMed  Google Scholar 

  12. He X, Xie J, Zhang D, Su Q, Sai X, Bai R, et al. Recombinant adeno-associated virus-mediated inhibition of microRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta 1 pathways. Hepatology. 2015;61:2008–17.

    Article  CAS  PubMed  Google Scholar 

  13. Zhu D, He X, Duan Y, Chen J, Wang J, Sun X, et al. Expression of microRNA-454 in TGF-beta1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. Parasit Vectors. 2014;7:148.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Carson JP, Ramm GA, Robinson MW, McManus DP, Gobert GN. Schistosome-induced fibrotic disease: the role of hepatic stellate cells. Trends Parasitol. 2018;34:524–40.

    Article  CAS  PubMed  Google Scholar 

  15. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76–99.

    Article  CAS  PubMed  Google Scholar 

  16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21–4.

    Article  CAS  PubMed  Google Scholar 

  19. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277:2015–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 2012;4:121ra18.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53:209–18.

    Article  CAS  PubMed  Google Scholar 

  23. He X, Xie J, Wang Y, Fan X, Su Q, Sun Y, et al. Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33. PLoS Pathog. 2018;14:e1006957.

    Article  PubMed  PubMed Central  Google Scholar 

  24. He X, Wang Y, Fan X, Lei N, Tian Y, Zhang D, et al. A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III. J Hepatol. 2020;72:519–27.

    Article  CAS  PubMed  Google Scholar 

  25. Huang Y, Fan X, Tao R, Song Q, Wang L, Zhang H, et al. Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway. J Cell Physiol. 2018;233:6693–704.

    Article  CAS  PubMed  Google Scholar 

  26. Yang YL, Wang FS, Li SC, Tiao MM, Huang YH. MicroRNA-29a alleviates bile duct ligation exacerbation of hepatic fibrosis in mice through epigenetic control of methyltransferases. Int J Mol Sci. 2017;18:192.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kumar V, Mondal G, Dutta R, Mahato RI. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis. Biomaterials. 2016;76:144–56.

    Article  CAS  PubMed  Google Scholar 

  28. Andrews W, Barber M, Hernadez-Miranda LR, Xian J, Rakic S, Sundaresan V, et al. The role of Slit-Robo signaling in the generation, migration and morphological differentiation of cortical interneurons. Dev Biol. 2008;313:648–58.

    Article  CAS  PubMed  Google Scholar 

  29. Yuen DA, Robinson LA. Slit2-Robo signaling: a novel regulator of vascular injury. Curr Opin Nephrol Hypertens. 2013;22:445–51.

    Article  CAS  PubMed  Google Scholar 

  30. Cornide-Petronio ME, Barreiro-Iglesias A. Role of Slit and Robo proteins in the development of dopaminergic neurons. Dev Neurosci. 2013;35:285–92.

    Article  CAS  PubMed  Google Scholar 

  31. Dickinson RE, Duncan WC. The SLIT-ROBO pathway: a regulator of cell function with implications for the reproductive system. Reproduction. 2010;139:697–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Huang T, Kang W, Cheng AS, Yu J, To KF. The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers. BMC Cancer. 2015;15:950.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ballard MS, Hinck L. A roundabout way to cancer. Adv Cancer Res. 2012;114:187–235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yuen DA, Huang YW, Liu GY, Patel S, Fang F, Zhou J, et al. Recombinant N-terminal Slit2 Inhibits TGF-beta-induced fibroblast activation and renal fibrosis. J Am Soc Nephrol. 2016;27:2609–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Chang J, Lan T, Li C, Ji X, Zheng L, Gou H, et al. Activation of Slit2-Robo1 signaling promotes liver fibrosis. J Hepatol. 2015;63:1413–20.

    Article  CAS  PubMed  Google Scholar 

  36. Song Q, Zhang H, He J, Kong H, Tao R, Huang Y, et al. Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway. Ther Adv Med Oncol. 2020;12:1758835920937890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang WJ, Fang ZM, Liu WQ. NLRP3 inflammasome activation from Kupffer cells is involved in liver fibrosis of Schistosoma japonicum-infected mice via NF-kappaB. Parasit Vectors. 2019;12:29.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lv WJ, Huang JY, Li SP, Gong XP, Sun JB, Mao W, et al. Portulaca oleracea L. extracts alleviate 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice. Front Nutr. 2022;9:986943.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Li B, Zhou J, Luo Y, Tao K, Zhang L, Zhao Y, et al. Suppressing circ_0008494 inhibits HSCs activation by regulating the miR-185-3p/Col1a1 axis. Front Pharmacol. 2022;13:1050093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.

    Article  CAS  PubMed  Google Scholar 

  41. Wheeler G, Valoczi A, Havelda Z, Dalmay T. In situ detection of animal and plant microRNAs. DNA Cell Biol. 2007;26:251–5.

    Article  CAS  PubMed  Google Scholar 

  42. Pottier N, Cauffiez C, Perrais M, Barbry P, Mari B. FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. Trends Pharmacol Sci. 2014;35:119–26.

    Article  CAS  PubMed  Google Scholar 

  43. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–32.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Labbé E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Can Res. 2007;67:75–84.

    Article  Google Scholar 

  45. Morais CN, Carvalho Bde M, Melo WG, Melo FL, Lopes EP, Domingues AL, et al. Correlation of biological serum markers with the degree of hepatic fibrosis and necroinflammatory activity in hepatitis C and schistosomiasis patients. Mem Inst Oswaldo Cruz. 2010;105:460–6.

    Article  PubMed  Google Scholar 

  46. El-Bassiouni NE, Nosseir MM, Madkour ME, Zoheiry MM, Bekheit IW, Ibrahim RA, et al. Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma. Mol Biol Rep. 2012;39:6843–50.

    Article  CAS  PubMed  Google Scholar 

  47. Liu P, Wang M, Lu XD, Zhang SJ, Tang WX. Schistosoma japonicum egg antigen up-regulates fibrogenesis and inhibits proliferation in primary hepatic stellate cells in a concentration-dependent manner. World J Gastroenterol. 2013;19:1230–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Huang YH, Tiao MM, Huang LT, Chuang JH, Kuo KC, Yang YL, et al. Activation of Mir-29a in activated hepatic stellate cells modulates its profibrogenic phenotype through inhibition of histone deacetylases 4. PLoS ONE. 2015;10:e0136453.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Lin HY, Wang FS, Yang YL, Huang YH. MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice. Cells. 2019;8:1298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y. MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice. Mol Ther. 2016;24:1848–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22:S73–8.

    Article  CAS  PubMed  Google Scholar 

  52. Herbert DR, Orekov T, Perkins C, Finkelman FD. IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis. J Immunol. 2008;181:7214–20.

    Article  CAS  PubMed  Google Scholar 

  53. Tebeje BM, Harvie M, You H, Loukas A, McManus DP. Schistosomiasis vaccines: where do we stand? Parasit Vectors. 2016;9:528.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the staff of the Department of Parasitology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, for their help with parasite infections.

Funding

This study was supported by the National Science and Technology Major Project (no. 2014ZX10005001; no. 2018ZX10302204-001) and the Health Commission of Hubei Province scientific research project (no. WJ2021M20). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Hongyan Kong, Dandan Xiang, Shuaiwen Huang, Xin Xu, Jinan He, Lanyue Pan, Ran Tao, Haijing Yu & Jiaquan Huang

  2. Cancer Institute, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Peking University Shenzhen Hospital, Shenzhen Peking University-the Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China

    Qiqin Song

  3. Department of Gastroenterology, The People’s Hospital of Jianshi, Enshi, China

    Wenjiang Hu

  4. Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Shusen Guo

Authors
  1. Hongyan Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiqin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenjiang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shusen Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dandan Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuaiwen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jinan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lanyue Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ran Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Haijing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jiaquan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HK, QS, and JH designed the study. HK, QS, WH, SG, DX, SH, XX, JH, LP, RT, and HY acquired the experimental data. HK and JH contributed to data analyses and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jiaquan Huang.

Ethics declarations

Ethics approval and consent to participate

The human study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (permit number: 20150103). Studies were performed according to the Declaration of Helsinki and with written informed consent from every patient. All animal experiments were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee (IACUC) of Tongji Medical College, Huazhong University of Science and Technology (IACUC no. 629).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Schematic diagram of MIR29A mouse construction. The Hipp11 (H11) locus is located within an intergenic region between the Eif4enif1 and Drg1 genes on mouse chromosome 11. The human MIR29A gene (NCBI ReferenceSequence: NR_029503.1) is located on human chromosome 7. For the conditional knock-in model, the “CAG-loxP-Stop-loxP-human MIR29A-polyA” cassette was inserted into the H11 locus (~ 0.7 kb 5' of the Eif4enif1 gene and ~ 4.5 kb 3' of the Drg1gene). Cas9 and gRNA were co-injected into fertilized eggs with a targeting vector for mouse production. The pups were genotyped by PCR followed by sequencing analysis.

Additional file 2: Figure S2.

Purity of isolated HSCs. (A, B) Representative results for HSC purification by flow cytometry and immunofluorescence. Insets show a higher magnification of the outlined area. Scale bar, 50 μm.

Additional file 3: Figure S3.

MIR29A mice had higher levels of miR-29a-3p in different organs. The miR-29a-3p expression levels in different organs of WT mice and MIR29A mice were determined by qPCR. Data are presented as the mean ± SD of three independent experiments. Significance was determined by the two-tailed Student’s t test. ***P < 0.001, ****P < 0.0001. miR-29a-3p: microRNA-29a-3p.

Additional file 4: Figure S4.

Alteration of parasite burden in the different groups during schistosome infection.Alteration of parasite burden in the infected WT mice and MIR29A mice.Alteration of parasite burden after administration of the miR-29a-3p agomir. Data are presented as the mean ± SD of three independent experiments. Significance was determined by the two-tailed Student’s t test (A) or one-way ANOVA with Tukey’s correction for comparisons between two groups (B). miR-29a-3p: microRNA-29a-3p.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, H., Song, Q., Hu, W. et al. MicroRNA-29a-3p prevents Schistosoma japonicum-induced liver fibrosis by targeting Roundabout homolog 1 in hepatic stellate cells. Parasites Vectors 16, 184 (2023). https://doi.org/10.1186/s13071-023-05791-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13071-023-05791-4

Keywords

Parasites & Vectors

ISSN: 1756-3305

Contact us